File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ekir.2021.01.004
- Scopus: eid_2-s2.0-85101322355
- WOS: WOS:000639562600011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
Title | Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease |
---|---|
Authors | |
Keywords | ADPKD FGF23 |
Issue Date | 2021 |
Citation | Kidney International Reports, 2021, v. 6, n. 4, p. 953-961 How to Cite? |
Abstract | Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and a loss of functioning renal mass, but a decline in glomerular filtration rate (GFR) and onset of end-stage renal disease (ESRD) occur late in the disease course. There is therefore a great need for early prognostic biomarkers in this disorder. Methods: We measured baseline serum fibroblast growth factor 23 (FGF23) levels in 192 patients with ADPKD from the Consortium for Radiologic Imaging Studies of PKD (CRISP) cohort that were followed for a median of 13 years and tested the association between FGF23 levels and change over time in height-adjusted total kidney volume (htTKV), GFR, and time to the composite endpoints of ESRD, death, and doubling of serum creatinine. Results: Patients in the highest quartile for baseline FGF23 level had a higher rate of increase in htTKV (0.95% per year, P = 0.0016), and faster rate of decline in GFR (difference of −1.03 ml/min/1.73 m2 per year, P = 0.005) compared with the lowest quartile, after adjusting for other covariates, including htTKV and genotype. The highest quartile of FGF23 was also associated with a substantial increase in risk for the composite endpoint of ESRD, death, or doubling of serum creatinine (hazard ratio [HR] of 2.45 in the fully adjusted model, P = 0.03). Conclusion: FGF23 is a prognostic biomarker for disease progression and clinically important outcomes in ADPKD, and has additive value to established imaging and genetic biomarkers. |
Persistent Identifier | http://hdl.handle.net/10722/316185 |
ISSN | 2023 Impact Factor: 5.7 2023 SCImago Journal Rankings: 1.377 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | El Ters, Mireille | - |
dc.contributor.author | Lu, Pengcheng | - |
dc.contributor.author | Mahnken, Jonathan D. | - |
dc.contributor.author | Stubbs, Jason R. | - |
dc.contributor.author | Zhang, Shiqin | - |
dc.contributor.author | Wallace, Darren P. | - |
dc.contributor.author | Grantham, Jared J. | - |
dc.contributor.author | Chapman, Arlene B. | - |
dc.contributor.author | Torres, Vicente E. | - |
dc.contributor.author | Harris, Peter C. | - |
dc.contributor.author | Bae, Kyongtae Ty | - |
dc.contributor.author | Landsittel, Douglas P. | - |
dc.contributor.author | Rahbari-Oskoui, Frederic F. | - |
dc.contributor.author | Mrug, Michal | - |
dc.contributor.author | Bennett, William M. | - |
dc.contributor.author | Yu, Alan S.L. | - |
dc.date.accessioned | 2022-08-24T15:49:32Z | - |
dc.date.available | 2022-08-24T15:49:32Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Kidney International Reports, 2021, v. 6, n. 4, p. 953-961 | - |
dc.identifier.issn | 2468-0249 | - |
dc.identifier.uri | http://hdl.handle.net/10722/316185 | - |
dc.description.abstract | Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and a loss of functioning renal mass, but a decline in glomerular filtration rate (GFR) and onset of end-stage renal disease (ESRD) occur late in the disease course. There is therefore a great need for early prognostic biomarkers in this disorder. Methods: We measured baseline serum fibroblast growth factor 23 (FGF23) levels in 192 patients with ADPKD from the Consortium for Radiologic Imaging Studies of PKD (CRISP) cohort that were followed for a median of 13 years and tested the association between FGF23 levels and change over time in height-adjusted total kidney volume (htTKV), GFR, and time to the composite endpoints of ESRD, death, and doubling of serum creatinine. Results: Patients in the highest quartile for baseline FGF23 level had a higher rate of increase in htTKV (0.95% per year, P = 0.0016), and faster rate of decline in GFR (difference of −1.03 ml/min/1.73 m2 per year, P = 0.005) compared with the lowest quartile, after adjusting for other covariates, including htTKV and genotype. The highest quartile of FGF23 was also associated with a substantial increase in risk for the composite endpoint of ESRD, death, or doubling of serum creatinine (hazard ratio [HR] of 2.45 in the fully adjusted model, P = 0.03). Conclusion: FGF23 is a prognostic biomarker for disease progression and clinically important outcomes in ADPKD, and has additive value to established imaging and genetic biomarkers. | - |
dc.language | eng | - |
dc.relation.ispartof | Kidney International Reports | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | ADPKD | - |
dc.subject | FGF23 | - |
dc.title | Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1016/j.ekir.2021.01.004 | - |
dc.identifier.scopus | eid_2-s2.0-85101322355 | - |
dc.identifier.volume | 6 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 953 | - |
dc.identifier.epage | 961 | - |
dc.identifier.isi | WOS:000639562600011 | - |